J. Gregory Dolan
No Rating Available
(Learn About Our Rating System)

J. Gregory Dolan, MD, MSME

Languages spoken: English

Clinical Locations

Primary Children's Hospital

Pediatric Hematology/Oncology
Salt Lake City

  • Dr. Dolan received his medical degree from the University of Washington and completed his Pediatric residency at Seattle Children´s Hospital. He went on to pursue his Pediatric Hematology and Oncology Fellowship and advanced fellowship in cellular/immunotherapy and bone marrow transplant at the Children’s Hospital of Philadelphia.

    He joined the faculty of the University of Utah in 2021 as an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology.

    Dr. Dolan’s clinical interests include the treatment of pediatric disorders requiring bone marrow transplant. He has an emphasis on high-risk hematologic malignancies and cellular therapy designed to reduce toxicity in patients with relapsed and refractory disease.

    His primary research focuses on outcomes of children treated with cellular/immunotherapy products. He also has an interest in understanding the emotional and spiritual challenges that arise as part of the journey for patients and families diagnosed with cancer.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Dolan received his medical degree from the University of Washington and completed his Pediatric residency at Seattle Children´s Hospital. He went on to pursue his Pediatric Hematology and Oncology Fellowship and advanced fellowship in cellular/immunotherapy and bone marrow transplant at the Children’s Hospital of Philadelphia.

    He joined the faculty of the University of Utah in 2021 as an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology.

    Dr. Dolan’s clinical interests include the treatment of pediatric disorders requiring bone marrow transplant. He has an emphasis on high-risk hematologic malignancies and cellular therapy designed to reduce toxicity in patients with relapsed and refractory disease.

    His primary research focuses on outcomes of children treated with cellular/immunotherapy products. He also has an interest in understanding the emotional and spiritual challenges that arise as part of the journey for patients and families diagnosed with cancer.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Assistant Professor (Clinical)
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Fellowship Pediatric Bone Marrow Transplant/Immunotherapy - Children’s Hospital of Philadelphia Advanced Fellow
    Fellowship Pediatric Hematology/Oncology - Children’s Hospital of Philadelphia Chief Fellow
    Graduate Training Medical Ethics - University of Pennsylvania MSME
    Fellowship Pediatric Hematology/Oncology - Children’s Hospital of Philadelphia Fellow
    Residency Pediatrics - Seattle Children’s Hospital, University of Washington Resident
    Professional Medical Medicine - University of Washington School of Medicine M.D.
    Fellowship Autoinflammatory Diseases - National Institutes of Health Research Fellow
    Undergraduate Zoology, Physiology - University of Wyoming B.S.
    Graduate Training Theology - University of Saint Mary of the Lake Postgraduate Studies
    Undergraduate Philosophy - Conception Seminary College B.A.

    Selected Publications

    Journal Article

    1. Muffly L, Liang EC, Dolan JG, Pulsipher MA (2024). How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL. Blood, 144(3), 253-261.
    2. Dolan JG, Hill DL, Faerber JA, Palmer LE, Barakat LP, Feudtner C (2021). Association of psychological distress and religious coping tendencies in parents of children recently diagnosed with cancer: A cross-sectional study. Pediatr Blood Cancer, 68(7), e28991. (Read full article)
    3. Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA (2021). Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol, 39(8), 920-930. (Read full article)
    4. Myers RM, Dolan J, Teachey DT (2021). Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. Expert Rev Clin Immunol, 16(10), 1029-1042. (Read full article)
    5. LaRiviere MJ, Avery RA, Dolan JG, Adamson PC, Zarnow DM, Xie Y, Avery SM, Kurtz GA, Hill-Kayser CE, Lustig RA, Lukens JN (2019). Emergent Radiation for Leukemic Optic Nerve Infiltration in a Child Receiving Intrathecal Methotrexate. Pract Radiat Oncol, 9(4), 226-230. (Read full article)
    6. Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, Khan J, Staudt LM, Helman LJ (2012). Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. Cancer Res, 72(22), 5889-99. (Read full article)
    7. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, Zalewski C, Kim HJ, Bishop R, Hill S, Paul SM, Kicker P, Phillips Z, Dolan JG, Widemann B, Jayaprakash N, Pucino F, Stone DL, Chapelle D, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R (2012). Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum, 64(7), 2375-86. (Read full article)
    8. Aubert P, Surez-Farias M, Mitsui H, Johnson-Huang LM, Harden JL, Pierson KC, Dolan JG, Novitskaya I, Coats I, Estes J, Cowen EW, Plass N, Lee CC, Sun HW, Lowes MA, Goldbach-Mansky R (2012). Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β. PLoS One, 7(11), e49408. (Read full article)

    Case Report

    1. Henrickson SE, Dolan JG, Forbes LR, Vargas-Hernndez A, Nishimura S, Okada S, Kersun LS, Brodeur GM, Heimall JR (2019). Gain-of-Function STAT1 Mutation With Familial Lymphadenopathy and Hodgkin Lymphoma. Front Pediatr, 7, 160. (Read full article)